RhumbLine Advisers
OYST

RhumbLine Advisers’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

RhumbLine Advisers’s Portfolio OYST Stock Details OYST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,531
Closed -$158K – 3315
2022
Q1 		$158K Buy
13,531
+2,568
+23% +$30.6K ﹤0.01% 2806
2021
Q4 		$200K Sell
10,963
-213
-2% -$2.7K ﹤0.01% 2835
2021
Q3 		$132K Buy
11,176
+525
+5% +$7.65K ﹤0.01% 2967
2021
Q2 		$183K Buy
+10,651
New +$202K ﹤0.01% 2930

Other funds holding OYST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

RhumbLine Advisers's OYST Position: Q2 2022 in Review

RhumbLine Advisers sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q2 2022, closing a stake of 13,531 shares — an estimated $158K sold.

RhumbLine Advisers first reported a position in OYST in Q2 2021 and held it in 4 quarters. The position peaked at $200K in Q4 2021. 61 funds tracked by Wall St. Rank hold OYST as of Q2 2022.

  • RhumbLine Advisers reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 13,531 Oyster Point Pharma, Inc. Common Stock shares in Q2 2022, an estimated $158K.
  • RhumbLine Advisers first reported a position in Oyster Point Pharma, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • RhumbLine Advisers's Oyster Point Pharma, Inc. Common Stock position peaked at $200K in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.